Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.56 |
| ▸ | CTSD | P07339 | 8/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.56 |
| ▸ | REN | P00797 | 6/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050491 | 0.89 | BACE1 (0.61) | BACE1CTSDBACE2REN | |
| SCHEMBL5049129 | 0.87 | BACE1 (0.76) | BACE1CTSDBACE2REN | |
| SCHEMBL5053628 | 0.86 | BACE1 (0.74) | BACE1CTSDBACE2REN | |
| SCHEMBL5055412 | 0.81 | BACE1 (0.65) | BACE1CTSDBACE2 | |
| SCHEMBL5051578 | 0.80 | BACE1 (0.50) | BACE1CTSDBACE2 | |
| SCHEMBL5055423 | 0.79 | BACE1 (0.74) | BACE1CTSDBACE2 | |
| SCHEMBL5049157 | 0.78 | BACE1 (0.75) | BACE1CTSDBACE2 | |
| SCHEMBL5049137 | 0.78 | BACE1 (0.60) | BACE1CTSDBACE2 | |
| SCHEMBL5051570 | 0.77 | BACE1 (0.54) | BACE1CTSDBACE2REN | |
| SCHEMBL5050493 | 0.76 | BACE1 (0.83) | BACE1CTSDBACE2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207527-A1 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof | COMENTIS, INC. (US) | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207527-A1 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 45/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.